Proudly Serving Canadians Since 2012Dutasteride
Classification: 5-alpha reductase enzyme
Standard: Synthetic 4-azasteroid
Estrogenic Activity None
Progestational Activity None
Water Retention: None
Aromatization: None
Hepatotoxicity None
Recommended Dosage: 0.5 mg/day
Dutasteride General Info
Dutasteride is a 5-alpha reductase enzyme inhibitor developed in 1997 and since then accepted and widely used worldwide in clinical medicine and bodybuilding. FDA approves Dutasteride as a safe and effective treatment for benign prostate enlargement (BPH).
5-alpha Reductases General Info
5-alpha-Reductases are enzymes that are responsible for steroid metabolism. The reductase enzymes located in androgenic tissues (prostate gland, skin, and hair follicles) convert steroids into metabolites. There are three types of isoenzymes of the 5 alpha-reductase SRD5A1/SRD5A2 and SRD5A3.
Conversion examples
Testosterone is converted into 5-alpha Dihydrotestosterone
Nandrolone is converted into 5-alpha Dihydronandrolone
Cortisol is converted into 5-alpha Dihydrocortisol
Progesterone is converted into 5-alpha Dihydroprogesterone
Steroid metabolites are crucial for proper body development and functioning. However, the high concentration of Testosterone steroid metabolite Dihydrotestosterone (DHT) in the prostate gland causes benign prostate enlargement (hyperplasia). In scalp tissues, the excess DHT levels cause hair loss.
Dutasteride Main Benefits
Dutasteride is a second-generation reductase inhibitor that inhibits all three types of isoenzymes (SRD5A1/SRD5A2/SRD5A3) of the 5-alpha reductase enzyme, which ultimately leads to DHT conversion inhibition in prostate, skin, and scalp tissues. Dutasteride is considered more effective than the first-generation reductase inhibitors because the first generation of inhibitors only inhibits one or two types of isozymes of the 5-alpha reductase enzyme.
Dutasteride Clinical Trial
Clinical Endocrinology and Metabolism (USA)
Study Type: Clinical Trial
Actual Enrollment:399 men with benign prostatic hyperplasia
Sexes Eligible for Trial: Men
Intervention Model: Parallel Assignment
Primary Purpose: Inhibition in DHT levels
Experimental Group
Patients received 0.5 mg and 5 mg of Dutasteride a day for 24 weeks.
Results
5 mg/day caused a 98% reduction in DHT levels
0.5 mg/day caused a 95% reduction in DHT levels
Dutasteride Administration
Prevention or Treatment for Benign Prostatic Hyperplasia
Dutasteride 0.5 mg a day
Androgenicity Reduction of AAS
Dutasteride 0.5 mg a day or every other day (EOD) for the entire AAS cycle.
Please note that Dutasteride is very effective and primarily used to lower the androgenicity of such compounds as testosterone, methyltestosterone, and fluoxymesterone.
Dutasteride Possible Side Effects
The most common side effect associated with Dutasteride intake is the reduced sex drive. Less than 5% of users had an allergic reaction to the drug.
Dosage and packing: 0.5mg/30tabs